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As of 2011, cancer was the leading cause
of death in the United States, second only
to heart disease. As cancer continues to
become an ever-increasing threat to human
health, the race is on to find an effective
telomerase inhibitor. This inhibitor has
to be functional enough to render the
cancer cell unable to divide, while leaving
the surrounding healthy cells relatively
untouched. Research has established that
the molecular structure of a compound
known as BIBR 1532 has proven to be
an effective telomerase inhibitor. Cancer
is often referred to as being “immortal”
because of its ability to divide an infinite
amount of times. Normal cells are limited
in the number of times they can divide by
the caps on the ends of their chromosomes,
called telomeres. These caps become
degraded over time, signaling the cell to die
when they become too short. An enzyme
known as telomerase lengthens the ends
of telomeres in cancer cells, granting them
immortality. Current research has shown
that BIBR 1532 inhibits telomerase by
preventing it from extending the copied
strand any further than the length of the
original strand of DNA. If telomerase is
inhibited, the telomeres of cancer cells can
no longer be elongated. Stripped of their
immortality, the telomeres of cancer cells
will become degraded and die. Research has
not yet discovered what portion of BIBR
1532 causes it to be such a good telomerase
inhibitor. Research has shown that there are
three substructures that must be present in
order for it to act as a telomerase inhibitor:
an aromatic ring containing a carboxylic
acid and a conjugated amine group.
During the summer of 2013, three novel
compounds were made via synthesis of
cinnamoyl chloride derivatives. These
three compounds all contain active sites
that are identical to those identified on
BIBR 1532, with one key difference in
the element attached to the aromatic
ring. The compounds were purified and
then tested against PC3 prostate cancer
cell lines. Prostate, breast, and pancreatic
cancers all have relatively high levels of
telomerase activity, which is a primary
reason why prostate cancer was chosen
as a target cell line. The compounds were
tested at three different concentrations:
50uM, 75uM, 100uM. Drug assay
were performed in order to determine
at which concentration the compounds

50
GVSU McNair Scholars Journal

showed significant anti-cancer activity,
while leaving behind enough cancer
cells to harvest telomerase and test for
telomerase inhibition. After performing
the assays, it was determined that the
ideal concentration of the compounds was
75uM. All three compounds were shown
to be more effective than BIBR 1532 at
this concentration. The next step will be
to test for telomerase inhibition using the
TRAPeze assay. If these compounds prove
to be telomerase inhibitors, it would be
a breakthrough as to how BIBR 1532
functions and could potentially lead to a
more effective cancer treatment. While the
compounds were tested using metastatic
prostate cancer cells, these potential
treatments have applications in both breast
and pancreatic cancers as well.
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